REMS vigabatrin refers to the FDA-mandated Risk Evaluation and Mitigation Strategy required for patients using vigabatrin. Due to the risk of irreversible vision loss, this program ensures strict monitoring, including baseline and regular eye exams, to safeguard patients while benefiting from vigabatrin’s effectiveness in treating severe seizure disorders like infantile spasms.